The low-osmolar contrast agent iodixanol shows a slight, though nonsignificant, ability to protect against contrast-induced nephropathy (CIN) compared with other low osmolar contrast media (LOCM), according to a meta-analysis of over 7,000 patients. The one clear advantage for iodixanol, according to the results published online July 20, 2010, ahead of print in Circulation: Cardiovascular Interventions, appears to be against 1 LOCM in particular, iohexol.
